Epcoritamab is under clinical development by Genmab and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Nodal Marginal Zone B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Epcoritamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epcoritamab overview

Epcoritamab-Bysp (Epkinly / Tepkinly) is a monoclonal antibody which acts as anti antineoplastic agent. It is formulated as solution for subcutaneous route of administration. Epkinly is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
Epcoritamab (GEN-3013) is under development for the treatment of lymphoma, relapsed and refractory chronic lymphocytic leukemia, Richter's Syndrome, diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma, follicular lymphoma, Burkitt-like lymphoma/leukemia, nodal marginal zone b-cell lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma (nodal marginal zone B-cell lymphoma and extranodal marginal zone B-cell lymphoma), high-grade b-cell lymphoma, small lymphocytic lymphoma and B-cell non-Hodgkin lymphoma, indolent NHL. The drug candidate is administered subcutaneously. It is a bi-specific antibody targeting CD20 and CD3. It is developed based on DuoBody technology that generates stable bi-specific antibody therapeutics.

Genmab overview

Genmab is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company’s marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan and the US. Genmab is headquartered in Copenhagen, Denmark.

For a complete picture of Epcoritamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.